WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

• 

• Julien Taieb, MD, PhD

  Professor
  Université Paris Cite (Descartes)
  Hôpital Européen Georges-Pompidou
  Paris, France

  Disclosures

  Julien Taieb, MD, PhD has the following relevant financial relationships:
  Consultant or advisor for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
  peaker or member of speakers bureau for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
  Research funding from: Pierre Fabre

• 

• Chiara Cremolini, MD, PhD

  Professor of Medical Oncology
  University of Pisa
  Pisa, Italy

  Disclosures

  Chiara Cremolini, MD, PhD has the following relevant financial relationships:
  Consultant or advisor for: Amgen Inc.; Merck; Pierre Fabre; SERVIER; Nordic Pharma
  Speaker or member of speakers bureau for: Bayer; Merck Sharp & Dohme; SERVIER; Pierre Fabre
  Research funding from: Bayer; Merck; SERVIER

• 

• Harpreet Wasan, MD

  Professor and Consultant in Medical Oncology
  Division of Cancer
  Hammersmith Hospital
  Imperial College Healthcare London
  London, United Kingdom

  Disclosures

  Harpreet Wasan, MD, has the following relevant financial relationships:
  Consultant or advisor for: ARCAD (Pancreas Academic); Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Celgene Corporation; Erytech Pharma; FM; Genentech; Incyte Corporation; NICE/BSI expert; Merck KGaA; ONCOSIL; SERVIER; SIRTEX Medical; Roche; Pierre Fabre; Pfizer, Inc.; Zymeworks
  Speaker or member of speakers bureau for: Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Erytech Pharma; FM; Genentech; Incyte Corporation; Merck KGaA; Roche; SERVIER; SIRTEX Medical; Pierre Fabre; Pfizer, Inc.; Zymeworks
  Research funding from: Merck Serono; Merck Sharp & Dohme; Pfizer, Inc.; SIRTEX Medical

• 

• Eric Van Cutsem, MD, PhD

  Professor of Medicine
  Head of Digestive Oncology
  University Hospital Leuven
  Leuven, Belgium

  Disclosures

  Eric Van Cutsem, MD, PhD has the following relevant financial relationships:
  Consultant or advisor for: AbbVie Inc.; ALX; Array BioPharma; Astellas Pharma, Inc.; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Incyte Corporation; Ipsen; Merck Sharp & Dohme; Merck KGaA; Mirati; Nordic Bioscience; Novartis; Pierre Fabre; Pfizer, Inc.; Roche; Seagen Inc.; SERVIER; Taiho Pharmaceutical Co., Ltd; Takeda; Terumo Medical Corporation; Zymeworks
  Research funding from: Amgen Inc.; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Ipsen; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER

• 

• Sebastian Stintzing, MD

  Professor of Medicine
  Head of the Department of Hematology,
  Oncology, and Cancer Immunology (CCM)
  Charité-Universitaetsmedizin Berlin
  Berlin, Germany

  Disclosures

  Sebastian Stintzing, MD, has the following relevant financial relationships:
  Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
  Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Isofol; LEO Pharma, Inc.;
  Research funding from: Merck KGaA; Pierre Fabre; SERVIER; Roche

Editors

• Keisha Peters, MSc

  Medical Education Director, WebMD Global, LLC

  Disclosures

  Keisha Peters, MSc, has no relevant financial relationships.

• Eloise Ballard, PhD

  Scientific Content Manager, WebMD Global, LLC

  Disclosures

  Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

• Leigh Schmidt, MSN, RN, CNE, CHCP

  Associate Director, Accreditation and Compliance, Medscape, LLC

  Disclosures

  Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.